United States Value-Based Reimbursement Models for Cell and Gene Therapies Market

Global value‑based reimbursement models for cell and gene therapies market size was valued at USD 1.19 billion in 2025. Assuming the United States captures roughly 45 % of the worldwide spend on advanced therapeutics, the U.S. segment is estimated at USD 0.54 billion in 2025, projected to rise from USD 0.58 billion in 2026 to USD 1.04 billion by 2034, reflecting a CAGR of 8.9 % over the forecast horizon.

www.intelmarketresearch.com/united-states-value-based-reimbursement-models-for-cellgene-therapies-market-50003
United States Value-Based Reimbursement Models for Cell and Gene Therapies Market Global value‑based reimbursement models for cell and gene therapies market size was valued at USD 1.19 billion in 2025. Assuming the United States captures roughly 45 % of the worldwide spend on advanced therapeutics, the U.S. segment is estimated at USD 0.54 billion in 2025, projected to rise from USD 0.58 billion in 2026 to USD 1.04 billion by 2034, reflecting a CAGR of 8.9 % over the forecast horizon. www.intelmarketresearch.com/united-states-value-based-reimbursement-models-for-cellgene-therapies-market-50003
United States ValueBased Reimbursement Models for Cell Gene Therapies Market 2026 to 2034
US cell and gene therapy reimbursement market was valued at USD?0.58?billion in 2026 and projected to reach USD?1.04?billion by 2034, at a CAGR of 8.9%.
0 Комментарии 0 Поделились